2013 2018 System in Integrative Biology T32 Grant – (Role: Participating Faculty) 2013 2018 Mouse Pathobiology: Models of Human Disease T32 Grant – (Role: Participating Faculty) 2013 2018 Medical Scientist Training Program T32 Grant – (role: Participating Faculty) Pending Submissions: 2015 - 2020 NCI R01(PAR 13-302) Phosphatase Activation as Therapeutic – Strategy for Chronic Lymphocytic Leukemia. (Role: PI) 2015 - 2020 U54 CCNE Ohio Center for Nanotechnology Excellence. – – Integration of Nano-fluidic Electroporation to identify and characterize leukemic stem cell properties and drug resistance in leukemia (Role: Co-Leader, Project 4) Research Grants- funded (past): 2009 2014 NCI SPORE P50 CA140158-05 - Experimental therapeutics of – leukemia Project 3: Lenalidomide as an Immune Modulating – Agent for Chronic Lymphocytic Leukemia. (Role: 2012 - 2013 10010859-45024 Boehringer Ingelheim (PI:Marcucci) In vitro evaluation of MAb 33.1 on primary CD33 antibody, alone and in combination with either lenalidomide or decitabine. Muthusamy Co-Investigator 2011 2013 NCCN (approved for funding- Declined) (PI: A Muthusamy) – Phase I/II study of the gamma-chain receptor cytokine IL-21 + oftaumumab in previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and B-prolymphocytic leukemia (PLL). (Role: PI) 2008 2013 NIH-RO1- CA135243-01 (PI: Lee) Targeted Lipoplexes for – oligonucleotide delivery to Acute Myeloid Leukemia (PIs-Robert Lee and Guido Marcucci) Muthusamy-Co-investigator 2007 2010 Leukemia & Lymphoma Society- Translational Grant – CD37 with Small Modular Immune pharmaceutical TRU16 (PI-John Byrd-
2013 – 2018 System in Integrative Biology T32 Grant (Role: Participating Faculty) 2013 – 2018 Mouse Pathobiology: Models of Human Disease T32 Grant (Role: Participating Faculty) 2013 – 2018 Medical Scientist Training Program T32 Grant (role: Participating Faculty) Pending Submissions: 2015 - 2020 NCI R01(PAR 13-302) – Phosphatase Activation as Therapeutic Strategy for Chronic Lymphocytic Leukemia. (Role: PI) 2015 - 2020 U54 – CCNE – Ohio Center for Nanotechnology Excellence. Integration of Nano-fluidic Electroporation to identify and characterize leukemic stem cell properties and drug resistance in leukemia (Role: Co-Leader, Project 4) Research Grants- funded (past): 2009 – 2014 NCI SPORE P50 CA140158-05 - Experimental therapeutics of leukemia – Project 3: Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia. (Role: 2012 - 2013 10010859-45024 Boehringer Ingelheim (PI:Marcucci) In vitro evaluation of MAb 33.1 on primary CD33 antibody, alone and in combination with either lenalidomide or decitabine. Muthusamy Co-Investigator 2011 – 2013 NCCN (approved for funding- Declined) (PI: Muthusamy) A Phase I/II study of the gamma-chain receptor cytokine IL-21 + oftaumumab in previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and B-prolymphocytic leukemia (PLL). (Role: PI) 2008 – 2013 NIH-RO1- CA135243-01 (PI: Lee) Targeted Lipoplexes for oligonucleotide delivery to Acute Myeloid Leukemia (PIs-Robert Lee and Guido Marcucci) Muthusamy-Co-investigator 2007 – 2010 Leukemia & Lymphoma Society- Translational Grant CD37 with Small Modular Immune pharmaceutical TRU16 (PI-John Byrd-
Muthusamy_CV_031615_raj_lh.docx